Skyscape Web Viewer : The Maudsley Prescribing Guidelines in Psychiatry : Main Index

View All
Renal impairment
Renal impairment in patients anti-dementia drugs antidepressants antipsychotics anxiolytics and hypnotics classification of stages clinical guidance lithium methadone monitoring mood-stabilisers other psychotropic drugs recommended psychotropic drugs Renal impairment
repetitive transcranial magnetic stimulation (rTMS) for catatonia for negative symptoms in schizophrenia for tardive dyskinesia
Reported associations between antidepressants and increased prolactin
Response assessment
Restarting after a break in treatment
Restarting medication up to 2 weeks after stopping oral treatment
Restarting psychotropic medications after a break in treatment after neuroleptic malignant syndrome after period of non-compliance
Restlessness (akathisia) 43 Akathisia Extrapyramidal symptoms Relative adverse effects - a rough guide
Restraint, exacerbating risks in drug-induced excited states
Restricted repetitive behaviours and interests, autism spectrum disorder
restricted repetitive behaviours and interests (RRBIs), core symptom of autism spectrum disorder
Reticulocyte count, psychotropic agent effects
Rilpivirine, psychiatric adverse reactions
Risk/extent of antipsychotic-induced weight gain (drugs in αbetical order)
Risk factors for orthostatic hypotension
Risk of perioperative blood loss and blood transfusion in SSRI users compared with non-SSRI users
Risks and management of various drugs in pregnancy
Risks to people with epilepsy
Risperdal Consta
Risperidone Alternatives to clozapine Antipsychotic prophylaxis Antipsychotic response - to increase the dose, to switch, to add or just wait - what is the right move? Antipsychotics - minimum effective doses bipolar disorder clozapine augmentation efficacy equivalent dose General introduction glucose tolerance impairment association in overdose in overdose\| maximum dose
risperidone intramuscular injection (Rykindo) 100
risperidone ISM (in situ microparticles) 81 Plasma level monitoring of psychotropic drugs Risperidone long-acting injection Site of administration of intramuscular injections
risperidone long-acting injections (RLAIs) 12 approximate dose equivalence bipolar disorder blood levels following discontinuation Depot antipsychotics - summary of pharmacokinetics doses and frequencies equivalent doses Equivalent doses intramuscular injections plasma concentrations timescale Risperidone long-acting injection Rykindo subcutaneous injections switching from
RISQ-PATH study
rivastigmine, Alzheimerâ™s disease
road traffic accidents (RTAs), psychotropic drugs and driving impairment
Routine monitoring, mitigating serious consequences of non-adherence
Safer prescribing, older people/dementia
Safety in older patients/dementia